Real-World Treatment Patterns And Survival Of Braf V600-Mutated Metastatic Non-Small Cell Lung Cancer Patients.

9096 Background: There is limited evidence on clinical outcomes in patients with BRAF-mutated non-small cell lung cancer (NSCLC) treated outside the controlled environs of clinical trials. To address this gap, we described treatment patterns and survival in such patients evaluated and treated at selected US academic cancer centers in 2009 -2016. Methods: This was a cross-sectional, retrospective medical record review of BRAF V600-mutated metastatic NSCLC patients from 7 centers. Participants in current/ previous BRAF-related clinical trials were excluded. Onset of metastatic NSCLC defined the index date, which was required to occur ≥6 months before the record abstraction date. We described treatment patterns and used Kaplan-Meier analyses for overall survival (OS). Results: The study included 72 patients. At index, median age [range] was 65 [44 to 90] years, 61.1% were female, 66.7% were current/former smokers, and 70.8% had Stage IV NSCLC at diagnosis. Fifty-two patients received ≥1 line of systemic therapy for metastatic disease. Platinum-based doublet chemotherapy was the most common first-line (1L) regimen (76.9% of 1L recipients); no patient received 1L targeted therapy (TT). Of the 33 second-line (2L) treatment recipients 30.3% received TT, and 10 patients received TT in ≥3 lines. At time of review, 38 patients were deceased. Median (95%CI) OS from the index date was 31.0 (14.5, 63.8) months for all patients, and 45.9 (16.1, 62.4) months from 1L initiation among 1L recipients. Median (95%CI) OS was 56.5 (13.4, 89.1) months from metastatic onset for TT recipients and 27.2 (10.6, 64.6) months in those not treated with TT. Patients (26) who had a BRAF test result < 3 months from metastatic onset had substantially shorter median survival (14.1 months) than patients (21) who had a test result ≥3 months after onset (52.7 months). Conclusions: These findings indicate that survival expectations of BRAF V600-mutated metastatic NSCLC patients may be higher than metastatic NSCLC patients without an oncogenic driver. The data also show patients who received TT had numerically longer OS from metastatic onset than patients receiving usual care, adding to the evidence on the importance of TT in BRAF V600-mutant NSCLC.